SUMF1
Basic information
Region (hg38): 3:3700814-4467273
Links
Phenotypes
GenCC
Source:
- mucosulfatidosis (Definitive), mode of inheritance: AR
- mucosulfatidosis (Strong), mode of inheritance: AR
- mucosulfatidosis (Strong), mode of inheritance: AR
- mucosulfatidosis (Strong), mode of inheritance: AR
- mucosulfatidosis (Supportive), mode of inheritance: AR
- mucosulfatidosis (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Multiple sulfatase deficiency | AR | Audiologic/Otolaryngologic; Cardiovascular; Gastrointestinal; Musculoskeletal; Neurologic; Ophthalmologic | The condition can include hearing loss, and hearing testing has been recommended; Due to risk of cardiovascular sequelae, screening with electrocardiogram and echocardiogram has been recommended; Due to risk of gallbladder complications, radiologic screening has been recommended; Management guidlines include hip and spine imaging to screen for hip dysplasia and cervical spine instability; Due to risk of glaucoma, ophthalmologic screening and management has been recommended; As neurological complications have been described, urgent brain imaging has been recommended in the setting of acute neurologic changes | Audiologic/Otolaryngologic; Biochemical; Cardiovascular; Craniofacial; Dermatologic; Gastrointestinal; Musculoskeletal; Neurologic | 14476546; 11737681; 12757706; 12757705; 17657823; 18509892; 19066960; 19697114; 21224894; 29397290 |
ClinVar
This is a list of variants' phenotypes submitted to
- Multiple sulfatase deficiency (60 variants)
- not provided (2 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the SUMF1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 192 | 196 | ||||
missense | 16 | 168 | 195 | |||
nonsense | 26 | 29 | ||||
start loss | 3 | |||||
frameshift | 23 | 27 | ||||
inframe indel | 2 | |||||
splice donor/acceptor (+/-2bp) | 17 | 22 | ||||
splice region | 2 | 6 | 31 | 1 | 40 | |
non coding | 28 | 116 | 32 | 176 | ||
Total | 58 | 39 | 202 | 312 | 39 |
Highest pathogenic variant AF is 0.0000197
Variants in SUMF1
This is a list of pathogenic ClinVar variants found in the SUMF1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
3-3844731-T-C | Likely benign (Jul 16, 2018) | |||
3-3844734-G-C | not specified | Uncertain significance (Jun 09, 2022) | ||
3-3844798-G-A | not specified | Uncertain significance (Mar 25, 2024) | ||
3-3844817-A-G | not specified | Uncertain significance (Nov 19, 2022) | ||
3-3844928-A-C | not specified | Uncertain significance (Dec 20, 2023) | ||
3-3844978-G-C | not specified | Uncertain significance (Jun 11, 2024) | ||
3-3845037-C-T | Benign (Dec 31, 2019) | |||
3-3845092-A-C | not specified | Uncertain significance (Jun 09, 2022) | ||
3-3845100-C-T | Benign (Dec 31, 2019) | |||
3-3845122-C-A | not specified | Likely benign (Dec 08, 2023) | ||
3-3845131-G-T | not specified | Likely benign (Aug 21, 2023) | ||
3-3845212-C-T | not specified | Uncertain significance (Dec 14, 2023) | ||
3-3845230-A-C | not specified | Uncertain significance (Feb 06, 2024) | ||
3-3845264-A-T | not specified | Uncertain significance (Jun 29, 2023) | ||
3-3845404-C-T | not specified | Uncertain significance (May 09, 2024) | ||
3-3845471-A-G | not specified | Uncertain significance (Feb 14, 2023) | ||
3-3845499-G-A | not specified | Uncertain significance (Mar 01, 2024) | ||
3-3845558-A-G | not specified | Uncertain significance (May 18, 2023) | ||
3-3845589-G-C | not specified | Uncertain significance (Apr 20, 2023) | ||
3-3845625-C-T | Likely benign (Mar 01, 2023) | |||
3-3845629-C-G | not specified | Uncertain significance (Jan 30, 2024) | ||
3-3845704-A-G | not specified | Uncertain significance (May 08, 2024) | ||
3-3845731-C-T | not specified | Uncertain significance (Aug 16, 2021) | ||
3-3845793-C-T | Likely benign (Apr 16, 2018) | |||
3-3845801-C-T | not specified | Uncertain significance (Jan 23, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
SUMF1 | protein_coding | protein_coding | ENST00000272902 | 9 | 766468 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
2.28e-8 | 0.704 | 125708 | 0 | 40 | 125748 | 0.000159 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.499 | 236 | 215 | 1.10 | 0.0000116 | 2381 |
Missense in Polyphen | 68 | 80.545 | 0.84425 | 941 | ||
Synonymous | -0.756 | 96 | 87.0 | 1.10 | 0.00000506 | 749 |
Loss of Function | 1.31 | 15 | 21.6 | 0.695 | 0.00000109 | 232 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000725 | 0.000724 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000109 | 0.000109 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000890 | 0.0000879 |
Middle Eastern | 0.000109 | 0.000109 |
South Asian | 0.000392 | 0.000392 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Oxidase that catalyzes the conversion of cysteine to 3- oxoalanine on target proteins, using molecular oxygen and an unidentified reducing agent (PubMed:12757706, PubMed:15657036, PubMed:15907468, PubMed:25931126, PubMed:16368756, PubMed:21224894). 3-oxoalanine modification, which is also named formylglycine (fGly), occurs in the maturation of arylsulfatases and some alkaline phosphatases that use the hydrated form of 3- oxoalanine as a catalytic nucleophile (PubMed:12757706, PubMed:15657036, PubMed:15907468, PubMed:25931126, PubMed:16368756). Known substrates include GALNS, ARSA, STS and ARSE (PubMed:12757706, PubMed:15907468, PubMed:15657036). {ECO:0000269|PubMed:12757706, ECO:0000269|PubMed:15657036, ECO:0000269|PubMed:15907468, ECO:0000269|PubMed:16368756, ECO:0000269|PubMed:21224894, ECO:0000269|PubMed:25931126}.;
- Disease
- DISEASE: Multiple sulfatase deficiency (MSD) [MIM:272200]: A clinically and biochemically heterogeneous disorder caused by the simultaneous impairment of all sulfatases, due to defective post- translational modification and activation. It combines features of individual sulfatase deficiencies such as metachromatic leukodystrophy, mucopolysaccharidosis, chondrodysplasia punctata, hydrocephalus, ichthyosis, neurologic deterioration and developmental delay. {ECO:0000269|PubMed:12757705, ECO:0000269|PubMed:12757706, ECO:0000269|PubMed:15146462, ECO:0000269|PubMed:18157819, ECO:0000269|PubMed:21224894}. Note=The disease is caused by mutations affecting the gene represented in this entry. SUMF1 mutations result in defective post-translational modification of sulfatases. {ECO:0000269|PubMed:12757706}.;
- Pathway
- Lysosome - Homo sapiens (human);Metabolism of lipids;Post-translational protein modification;Metabolism of proteins;The activation of arylsulfatases;Gamma carboxylation, hypusine formation and arylsulfatase activation;Metabolism;Glycosphingolipid metabolism;Sphingolipid metabolism
(Consensus)
Recessive Scores
- pRec
- 0.0660
Intolerance Scores
- loftool
- 0.0554
- rvis_EVS
- -0.18
- rvis_percentile_EVS
- 40.36
Haploinsufficiency Scores
- pHI
- 0.0288
- hipred
- N
- hipred_score
- 0.416
- ghis
- 0.440
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.294
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Sumf1
- Phenotype
- growth/size/body region phenotype; cellular phenotype; craniofacial phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); liver/biliary system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); skeleton phenotype; immune system phenotype;
Gene ontology
- Biological process
- glycosphingolipid metabolic process;protein oxidation;post-translational protein modification
- Cellular component
- endoplasmic reticulum;endoplasmic reticulum lumen
- Molecular function
- oxidoreductase activity;protein homodimerization activity;Formylglycine-generating oxidase activity;cupric ion binding